Monday, November 22, 2021 Daily Archives

CureVac reallocating failed COVID vax capacity to support next-gen mRNA

by

Having abandoned its COVID-19 candidate CVnCoV, CureVac has switched up its manufacturing network in preparation for a second-generation messenger RNA (mRNA) vaccine. For the third quarter 2021, German biotech CureVac reported a loss of €143.5 million ($162 million) – a €106.4 million increase compared to the same period in 2020. According to the firm, the increase was in line with high development costs of CVnCoV, the firm’s first-generation mRNA vaccine targeting COVID-19. This was propped up due to a change…

November 22, 2021

Amneal to leverage Indian network to enter biomanufacturing space

by

With a robust biosimilars pipeline and an increasingly large footprint, Amneal is preparing to invest in biologics manufacturing capabilities. Amneal Pharmaceuticals has developed and commercialized numerous small molecule drugs and generics but according to the Indian press the firm is on the verge of entering the biomanufacturing space with a greenfield biologics plant in Ahmedabad on the cards. The interest in biologics was confirmed by Amneal spokesman Anthony Di Meo, but he said plans have not been finalized. “In terms…

November 22, 2021

Generate Biomedicines raises $370m to advance AI drug discovery tech

by

Generate Biomedicines has raised $370 million to further develop its artificial intelligence (AI) drug discovery technology, expand its team and build labs. The Cambridge, Massachusetts biotech completed a series B round last week, attracting investment from founding backer Flagship Pioneering and the Abu Dhabi Investment Authority (ADIA), the Alaska Permanent Fund and Altitude Life Science Ventures. Generate said the money will allow it to “advance and evolve†the platform and “scale the organization with top-tier scientific and computational talent.†It…

November 22, 2021